Til sammenligning opstod der frakturer hos 23/ 905 (2, 5%) af de kvindelige patienter, som fik behandling med komparator.
In the 3.5 year PROactive study, 44/ 870 (5.1%) of pioglitazone-treated female patients experienced fractures compared to 23/ 905 (2.5%) of female patients treated with comparator.